IP Library Granted Patent US 7,315,762
Granted Patent B2
US 7,315,762 · App. 10/759,732 · Granted Jan 1, 2008

Non-surgical incontinence treatment system and method

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,315,762
App. No.
10/759,732
Granted
Jan 1, 2008
Kind
B2
Abstract

Devices, systems, and methods can treat incontinence by heating between about 100 and about 800 cubic millimeters of endopelvic fascia for sufficient time to effect substantial collagenous tissue shrinkage. A probe body may directly engage the endopelvic fascia, or may be separated from the endopelvic fascia, heating through (for example) the vaginal wall. In either case, tissue-penetrating electrodes may be inserted from the probe body so as to heat the endopelvic fascia.

Claims (20)

1. A method for treating incontinence, the method comprising: aligning a probe body with a collagenous pelvic tissue; heating a treatment volume of at least 100 cubic millimeters of the collagenous tissue using the aligned probe body.

2. The method of claim 1 , wherein the treatment volume is separated from a urethra by at least about 1 cm.

3. The method of claim 2 , wherein the treatment volume is offset laterally from the urethra to a right side or left side.

4. The method of claim 2 , wherein the treatment volume comprises at least 300 cubic millimeters of collagenous tissue, wherein the heating is performed so that the treatment volume is heated to a temperature of at least 70° C. for a time of at least 30 seconds, wherein the treatment volume is offset laterally from the urethra to a right side of a patient, and further comprising heating another treatment volume offset laterally from the urethra to a left side of the patient, the other treatment volume comprising at least 300 cubic millimeters of collagenous tissue and heated to at least 70° C. for at least 30 seconds.

5. The method of claim 1 , wherein the treatment volume is heated to at least about 65° C. for at least about 100 seconds.

6. The method of claim 1 , wherein the treatment volume is heated to at least about 75° C. for at least about 10 seconds.

7. The method of claim 1 , further comprising applying a dwell time after a desired heating temperature is achieved so as to increase treatment tissue volume.

8. The method of claim 1 , wherein the treatment volume has a length orientation extending along a urethra, a depth orientation extending between the collagenous tissue and the probe body, and a width that is greater than the length of the treatment volume.

9. The method of claim 1 , wherein the treatment volume has a length orientation extending along a urethra, a depth orientation extending between the collagenous tissue and the probe body, and a width that is less than the length of the treatment volume.

10. The method of claim 1 , further comprising registering a position of the treatment volume along an axis of the urethra with reference to a guide body disposed within the urethra.

11. The method of claim 1 , further comprising registering a position of the treatment volume with reference to bone.

12. The method of claim 1 , wherein the probe is aligned so that an intermediate tissue is disposed between the probe body and the treatment volume.

13. The method of claim 12 , wherein the treatment volume comprises tissue separated from the aligned probe body by a distance within a range of about 2 to 8 mm.

14. The method of claim 12 , wherein the treatment volume comprises tissue separated from the aligned probe body by a distance within a range of about 2 to 4 mm.

15. The method of claim 12 , wherein the heating is performed so as to inhibit necrosis of the intermediate tissue.

16. The method of claim 15 , wherein the heating is performed while cooling the intermediate tissue.

17. The method of claim 15 , wherein the heating is performed without cooling of the intermediate tissue.

18. The method of claim 1 , wherein the heating is performed by tip movement of at least a pair of electrodes supported by the probe body.

19. The method of claim 18 , wherein the treatment volume increases as the tip movement speed decreases.

20. The method of claim 1 , wherein the treatment volume comprises at least 300 cubic millimeters of collagenous tissue.

Assignments (12)
SECURITY INTEREST Recorded Jul 22, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068469/0001 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA
Reel/Frame 068461/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2024
From: ENDO USA, INC.
To: ENDO OPERATIONS LIMITED
Reel/Frame 067245/0492 →
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: ASTORA WOMEN’S HEALTH, LLC
To: ENDO USA, INC.
Reel/Frame 067202/0768 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
SECURITY INTEREST Recorded Jun 8, 2017
From: ASTORA WOMEN'S HEALTH, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0278 →
RELEASE OF SECURITY INTEREST Recorded Aug 6, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: AMERICAN MEDICAL SYSTEMS, LLC; AMS RESEARCH, LLC; LASERSCOPE
Reel/Frame 036285/0146 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS, INC.; ENDO PHARMACEUTICALS, INC.; AMS RESEARCH CORPORATION; AMERICAN MEDICAL SYSTEMS, INC.; LASERSCOPE
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0440 →
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: AMS RESEARCH CORPORATION
Reel/Frame 032380/0053 →
SECURITY AGREEMENT Recorded Jul 22, 2011
From: AMS RESEARCH CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026632/0535 →